The effects of raloxifene and salmon calcitonin treatments on serum lipoprotein levels and bone mineral density in postmenopausal osteoporosis

Basit Öğe Kaydı
dc.authorscopusid6603502698
dc.authorscopusid56210458900
dc.authorscopusid8523409200
dc.contributor.authorKokino S.
dc.contributor.authorÖzdemir F.
dc.contributor.authorDemirba? D.
dc.date.accessioned2024-06-12T10:28:50Z
dc.date.available2024-06-12T10:28:50Z
dc.date.issued2004
dc.description.abstractPostmenopausal osteoporosis may lead an increased incidence of fractures in spine and hip joint. Several medications are currently available for prevention and treatment of osteoporosis. The purpose of the present study was to assess and compare the effects of raloxifene 60 mg/day and intranasal salmon calcitonin 200 IU/day on bone mineral density (BMD) and serum lipid profile. The salmon calcitonin study group and the raloxifene study group consisted of 29 and 30 patients, respectively. Serum levels of triglycerides and cholesterol were evaluated and BMD of lumbar vertebrae and femoral neck were measured by dual energy X-ray absorpsiometry (DEXA) at the baseline and at the end of 12 months of treatment. Although we found a decrease in value of triglycerides (t=0.591, p=0,560) and cholesterol (t=1.208, p=0.237) in the calcitonin group after the treatment with respect to pre-treatment values, the difference was not statistically significant. We determined statistically significant difference in values of triglycerides (t=3.123, p=0.004) and cholesterol (t=2.582, p=0.015) in raloxifene group after the treatment. We found statistically significant differences between pre and post treatment values of BMD of L2-L4 region in both of the groups (calcitonin group; t=-3.498, p=0.002, raloxifene group; t=-7.163, p=0.000). In BMD of femur neck, while the difference between pre and post treatment values were not significant in salmon calcitonin group (t=-0.673, p=0.507), we determined statistically significant difference in raloxifene group (t=-4.264, p=0.000).en_US
dc.identifier.endpage13en_US
dc.identifier.issn1302-0234
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-12344273295en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage8en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17454
dc.identifier.volume50en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofTurkiye Fiziksel Tip ve Rehabilitasyon Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone Mineral Density; Calcitonin; Cholesterol; Raloxifene; Triglyceridesen_US
dc.subjectCholesterol; Lipoprotein; Raloxifene; Salcatonin; Triacylglycerol; Adult; Article; Bone Density; Cholesterol Blood Level; Controlled Study; Drug Mechanism; Dual Energy X Ray Absorptiometry; Female; Femur Neck; Human; Lipoprotein Blood Level; Lumbar Vertebra; Major Clinical Study; Postmenopause Osteoporosis; Statistical Significance; Triacylglycerol Blood Levelen_US
dc.titleThe effects of raloxifene and salmon calcitonin treatments on serum lipoprotein levels and bone mineral density in postmenopausal osteoporosisen_US
dc.title.alternativePostmenopozal osteoporozda raloksifen ve salmon kalsitonin tedavilerinin serum lipoprotein düzeyleri ve kemik mineral yo?unlu? una etkilerien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu